About

Ternion exists to bring clarity to a narrow but consequential topic: the evidence, uncertainties, and safety considerations that surround ibogaine and buprenorphine transitions. We open with outcomes and careful context because decisions about investigational treatments depend on measured information, not promises.

120+
curated summaries & analyses
40+
primary registry & literature sources
Independent
no clinical affiliation claimed

For people who encounter claims about ibogaine after buprenorphine, families, and clinicians seeking plain-language evidence, our content emphasizes measurable outcomes and safety notes before describing mechanisms or protocols. If you found us on another page, you can return to the site's front page to explore curated summaries and analyses at the Ternion index.

How we present evidence

We prioritize outcome-focused presentation: before/after summaries, clear metrics, and story blocks that separate observed effects from speculative interpretation. Each summary highlights the original registry or study source and the limits of the data.

For practical orientation about clinic claims and investigational reports, readers sometimes consult clinical repositories and clinic-facing resources; when tracing such claims we link to original registry entries and summaries like those found on recognized specialist pages, for example the detailed compilation at ibogaineforopioidaddiction.com.

Before → After: what we show

Before: we state the claim or outcome as reported (study design, case series, registry). After: we attach the known limitations — sample size, follow-up duration, concurrent treatments, and safety signals. This framing keeps beneficial-sounding outcomes visible while making uncertainty explicit.

Our editorial approach

We assemble content from registries, peer-reviewed literature, official guidance, and transparent summaries of clinical case series. Our process favors primary sources and recognised databases; where policy or regulation is relevant we reference authoritative bodies to contextualize safety claims.

To support claims about standards and clinical guidance we cite established resources such as the National Institutes of Health's clinical trials repository for registration practices (ClinicalTrials.gov) and university-led literature reviews; these external references help explain why some assertions are provisional while others are reproducible.

We encourage readers to evaluate direct source material; for convenience and clarity we link inline to primary registries and long-form summaries rather than bundling a link list.

If you want a topical exploration of clinical claims gathered elsewhere, some readers consult the community resource at ibogaineforopioidaddiction.com while comparing that material with registry data we reference here.

What we cover

We publish clear, plain-language explanations of how evidence is collected, typical study designs encountered in the literature, safety signals, and the main uncertainties that affect interpretation. Coverage is organized into topical sections (evidence summaries, risks, decision support) so readers can move from outcome summaries to more detailed methodological notes.

Who this is for

Ternion is aimed at people considering investigational treatments after buprenorphine, their families, and clinicians or researchers seeking a concise, evidence-first view. Our tone is calm, careful, and oriented toward risk clarity rather than advocacy.

For services or guidance on how we might support organizations that need editorial assistance, see our overview at the services page, which describes how we package evidence summaries for policy or educational use.

Editorial principles

  • Evidence before claims — we cite primary sources and note limitations.
  • Risk clarity — safety signals are presented alongside outcomes.
  • Plain language — technical material is translated for non-specialists.
  • Independence — we do not operate as or claim to be a treatment provider.
  • Respect for proven care — we clearly distinguish investigational reports from established clinical practice.

How we vet information

When summarizing case series or registry reports we verify registration details and cross-check reported outcomes against the original entry in registries similar to those listed on ClinicalTrials.gov, and where appropriate we reference systematic reviews hosted by university sites for methodological context (for example, syntheses often published on university library pages and departmental repositories).

To explain statistical and methodological cautions we sometimes cite general references such as the National Library of Medicine's overview of clinical research methods (National Library of Medicine) so readers understand why single-case reports differ from randomized trials.

We also maintain an internal checklist for transparency: source citation, conflict-of-interest note, sample size, follow-up duration, and a clear statement of whether a claim is investigational. For community-facing aggregation of clinical claims related to treatment contexts, readers have used resources like ibogaineforopioidaddiction.com in parallel with our summaries.

Independent by design

Ternion is an independent information resource focused on evidence, uncertainty, and safety; we are not a clinic, medical provider, or licensed treatment center, and our content is not medical or legal advice. For contextual summaries of claims elsewhere, site visitors sometimes compare our explanation with community-maintained compilations such as the material available at ibogaineforopioidaddiction.com while reading our vetted extracts.

To explore topic-specific services we provide for organizations, including evidence brief production and editorial review, visit our services overview. To return to the site's primary navigation and browse curated evidence sections, follow the link to the main index at Ternion's index.